MedDataX Logo

Value of Von Willebrand Factor in Portal Hypertension

NCT ID: NCT01358123

Last Updated: 2015-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear. vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous pressure gradient (HVPG) is the current gold standard for the diagnosis of portal hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension (CSPH, HVPG \>=10mmHg) and its complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

NCT06694090

Liver Cirrhosis Portal Hypertension
NOT_YET_RECRUITING

Vienna Vascular Liver Disease Study

NCT03541057

Vascular Liver Disease Portal Vein Thrombosis Budd-Chiari Syndrome +4 more
RECRUITING

Predictive and Prognostic Significance of Age,Blood Tests,Comorbidities(ABC) Score,Cologne Watch(C-watch)Score and Rockall Score for Risk of Variceal Re-bleeding Among Cirrhotic Patients

NCT06335186

Upper Gastrointestinal Variceal Bleeding in Cirrhotic Patients
RECRUITING

Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic

NCT03580577

Liver Cirrhosis Venous Thromboembolism
UNKNOWN

Diagnosis of Variceal Bleeding and Its Control in Cirrhosis

NCT00188097

Cirrhosis
TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with alcoholic, viral (chronic hepatitis C), and cryptogenic liver cirrhosis are included. Portal hemodynamics are assessed by HVPG measurement, vWF-Ag levels were measured by ELISA. Results will be compared. 3 and 6 months mortality will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis Portal Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver cirrhosis

Exclusion Criteria

* no HVPG measurement
Minimum Eligible Age

18 Years

Maximum Eligible Age

98 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Arnulf Ferlitsch, MD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arnulf Ferlitsch, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Vienna

Vienna, Vienna, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Arnulf Ferlitsch, MD

Role: CONTACT

[email protected]
+43140400

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arnulf Ferlitsch

Role: primary

[email protected]
+436765666536

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

vwfcirr

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Haemostatic Imbalance in Patients With Chronic Liver Disease
NCT03589430 UNKNOWN
Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis
NCT03513887 COMPLETED
RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
NCT03061604 COMPLETED NA
ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension
NCT04267406 COMPLETED
Hepatic Venous Pressure Gradient and Platelet Activation in Chronic Liver Disease
NCT02618798 UNKNOWN
Hepatic Venous Pressure Gradient and Elastography in Porto-sinusoidal Vascular Disorder
NCT05719857 UNKNOWN NA
Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed
NCT06815770 NOT_YET_RECRUITING PHASE2/PHASE3
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
NCT01729611 COMPLETED
Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry
NCT01470547 COMPLETED
Non-Invasive Portal and Hepatic Vein Pressure Estimation
NCT06210178 RECRUITING NA
TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
NCT02485184 UNKNOWN NA
Clinical,Endoscopic and Radiological Assessment of Portal Hypertension in Children With Chronic Liver Diseases
NCT06097715 UNKNOWN NA
Efficacy and Safety of Intravenous Vitamin K1 in Management of Acute Variceal Bleeding
NCT06839352 COMPLETED PHASE4
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
NCT04797910 UNKNOWN
Heparin Like Effect in Acute Variceal Bleeding
NCT04111120 UNKNOWN
The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study
NCT01091233 WITHDRAWN
To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
NCT06066814 UNKNOWN
Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension
NCT02635815 COMPLETED
The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis
NCT02258048 WITHDRAWN
Utility of Renal Biomarkers in Cirrhosis
NCT01217983 COMPLETED
Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis
NCT02069457 COMPLETED
MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
NCT03438916 COMPLETED
WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis
NCT03195634 UNKNOWN
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography
NCT02757170 UNKNOWN PHASE4
Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia
NCT00005107 UNKNOWN PHASE1